What happens after neridronate treatment for CRPS Type 1

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational registry that tracks long-term outcomes after neridronate treatment for CRPS Type 1. Participants who previously received neridronate in CRPS-RISE or its open-label extension will complete online surveys about pain, medications, procedures, and daily functioning for up to two years. The study does not administer neridronate as part of the registry and collects limited safety information. The registries’ primary focus is on health status, CRPS-related clinical events, and disability over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants from CRPS-RISE

  1. Completion of four infusions of IP (neridronate 100 mg over a \~ 10-day period \[or the renally modified dosing, as applicable\] or placebo) in CRPS-RISE .
  2. Completed CRPS-RISE with a final trial visit at Week 6 (Visit 8) or later.

     Participants who meet both criteria will be provisionally enrolled pending post-trial unblinding and be included in the Provisionally Enrolled Study Cohort.

     After CRPS-RISE last patient last visit unblinding, only participants who meet the following neridronate exposure criterion #3 will continue in registry follow-up and be included in the Enrolled Study Cohort:
  3. Completion of 4-infusions of neridronate 100 mg over approximately a 10-day period in CRPS-RISE.
* Participants from the Open Label Extension (OLE)

  1. Completion of 4 infusions of neridronate 100 mg over approximately a 10-day period (or the renally modified dosing, as applicable) in the OLE.
  2. Completed OLE with a final trial visit at Week 6 (Visit 8) or later.

Exclusion Criteria:

There are no exclusion criteria.

Where it's running

• CRPS-RISERegistry
  Durham, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Joel Castellanos, MD — UCSD
• Study coordinator: CRPS-RiseRegistry
• Email: CRPS-RiseRegistry@iqvia.com
• Phone: 877-834-5183

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CRPS of the hand: Contrast plus compression vs whirlpool therapy

  This randomized study tests whether a combined contrast therapy with intermittent compression helps people with CRPS-I in the hand and wrist more than whirlpool therapy.

  Recruiting Ankara Etlik City Hospital · Ankara, Yenimahalle · NCT07744269

• Neridronate extension study for CRPS-1

  This study tests IV neridronate in people with CRPS-1 who completed a previous trial, to see if it continues to help with pain and symptoms.

  Recruiting Phase 3 Ambros Therapeutics, Inc. · Phoenix, Arizona · NCT07857733

• IV neridronate for warm-type Complex Regional Pain Syndrome (CRPS-1) with a positive bone scan

  This trial will try IV neridronate to reduce pain and swelling in adults with recent-onset warm-subtype CRPS-1 who have a positive triple-phase bone scan.

  Recruiting at 33 sites Phase 3 Ambros Therapeutics, Inc. · Phoenix, Arizona and 32 other locations · NCT07210515

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.